首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Effect of 4-hydroxytamoxifen isomers on growth and ultrastructural aspects of normal human breast epithelial (HBE) cells in culture
Authors:Malet Catherine  Spritzer Poli  Cumins Caroline  Guillaumin Delhy  Mauvais-Jarvis Pierre  Kuttenn Frédérique
Institution:

a Department of Endocrinology and Reproductive Medicine, Hôpital Necker, 149 rue de Sèvres, 75743, Paris Cedex 15, France

b Centre Inter-Universitaire de Microscopie Electronique, Faculté Jussieu-Paris VI, 4 Place Jussieu, 75252, Paris Cedex 05, France

Abstract:In the search for a breast cancer prevention strategy which would avoid undesirable effects of orally administered tamoxifen, the percutaneous administration of the highly active metabolite 4OHTamoxifen (4OHTam) has been proposed. Percutaneous 4OHTam penetrates the skin to reach breast tissues. It, thus, avoids the hepatic first pass effect, and offers an optimal local/systemic effect. However, trans-4OHTamoxifen can spontaneously isomerize into the cis-isomer, which may have estrogen agonist action. The aim of this study was to examine the effect of cis-4OHTam on normal human breast epithelial (HBE) cells in culture.

Spontaneous isomerization of trans- into cis-4OHTam occurred within 24–48 h, but stabilized rapidly at a trans/cis ratio of 70/30, whether in stock solution, culture medium or cultured cells. The cis-4OHTam did not stimulate HBE cell growth according to histometric cell counts and scanning electron microscopy analysis, but inhibited E2-induced cell growth, albeit two to three times less than trans-4OHTam.

In conclusion, spontaneous isomerization of trans- to cis-4-OHTam is limited and 4OHTam retains a marked antiestrogenic effect. It may prove to be a useful alternative to tamoxifen in breast cancer prevention, especially if administered percutaneously.

Keywords:Antiestrogen  Breast cancer prevention  Breast cell growth  Hydroxytamoxifen isomers  Tamoxifen metabolism
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号